Scientists at the University of Cambridge have designed a bird flu vaccine with the help of artificial intelligence that guards against a wide array of virus variants rather than a single strain, according to Euronews.com. The work, published in Cell Reports Medicine, found the candidate gave broader protection and better survival outcomes than the vaccine currently held in stockpiles for pandemic planning. The research was led by Jonathan Heeney of Cambridge's Lab of Viral Zoonotics and carried out with the university's spinout company DIOSynVax Ltd.
Why it matters
Bird flu belongs to the RNA virus family, the same broad group that includes the coronaviruses behind COVID-19 and many other diseases that emerge from animals. Such viruses are a persistent concern for human health because they change quickly, producing new forms that can cross from animals to people and slip past the defenses built up by prior infection or vaccination. Current preparedness strategies depend on keeping supplies of vaccines aimed at individual variants that have already appeared, which means responses tend to arrive after a threat has already shifted shape.
According to Euronews.com, the Cambridge authors describe multi-strain vaccines of this kind as a significant shift for national biosecurity and for building more resilient public health systems. Heeney said the goal was to look ahead at how the virus might change instead of chasing it after the fact. He described the current approach as always being a step behind, responding with a strain that will by then have changed, and said the new method could allow an immediate response to epidemics and pandemics.
How the vaccine was designed
The team drew on genetic sequence data gathered by surveillance programs around the world, including samples from wildlife, livestock and people infected with bird flu. From that pool, they applied computational and evolutionary algorithms to create five synthetic antigens shaped by AI. Antigens are the active ingredients in vaccines; they prompt the immune system to mount a defense and train the body to recognize and fight a pathogen carrying that antigen later on.
The five designed antigens were meant to capture the global variety of bird flu viruses and to make it harder for the virus to escape immune protection. Heeney said AI greatly accelerates the design stage, after which candidates can be examined in the laboratory to confirm they are sturdy and safe.
Animal results and comparison with the stockpiled jab
In the experiments, the vaccine fully protected mice and ferrets against a set of genetically distinct variants of the virus that causes bird flu. According to Euronews.com, all of those variants have caused human infections and are considered possible pandemic threats. When the same animals were immunized with the World Health Organization's existing bird flu vaccine, only half survived exposure to those viruses.
EurekAlert! reported that the Cambridge-developed vaccine outperformed the current stockpiled jab, while News-Medical reported that it fully protected animals in the experiments. Genetic Engineering and Biotechnology News described the results as showing the AI-designed candidate surpassing stockpiled vaccines in preclinical testing, and DongA Science reported that the DIOSynVax vaccine delivered complete protection against avian flu variants.
The broader effort fits a pattern for the Cambridge group. Earlier this year, the same team produced the first entirely AI-designed vaccine to be tested in humans, one intended to give durable protection against a wide range of viruses, including Ebola and members of the coronavirus group, even as those viruses mutate. The bird flu candidate is the latest in that series of vaccines whose active ingredient is built to defend against thousands of variants in a single shot.
What to watch
The next stage is human clinical trials, which would be needed before the vaccine could be deployed during an outbreak. The researchers also intend to extend the same design framework to seasonal influenza vaccines and to other RNA viruses that evolve rapidly.
